ResearcherUniversity of Colorado Cancer CenterActive in the last 2 years
John J. Arcaroli
Matched on OpenAlex author ID A5086504706. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2012: 2 papers · 2013: none · 2014: 1 paper · 2015: none · 2016: 1 paper · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: none · 2024: 1 paper
Papers 6
- Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tumor organoid library (PTOL). Co-author DOI 10.1371/journal.pone.0298808↗
- Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. Co-author DOI 10.2174/2212697x05666180516120907↗
- Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma. First author DOI 10.1097/mpa.0000000000000542↗
- A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma. Co-author DOI 10.1007/s10637-014-0083-8↗
- Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreati… Co-author DOI 10.1002/cam4.27↗
- Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Co-author DOI 10.1593/neo.111810↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Wells A. Messersmith · 6 shared papers, 2012–2024 · strength 0.40
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808↗
- Paper Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. DOI 10.2174/2212697x05666180516120907↗
- Paper Aldehyde Dehydrogenase 1B1 as a Modulator of Pancreatic Adenocarcinoma. DOI 10.1097/mpa.0000000000000542↗
- Todd M. Pitts · 2 shared papers, 2018–2024 · strength 0.25
- Paper Examination of Wnt signaling as a therapeutic target for pancreatic ductal adenocarcinoma (PDAC) using a pancreatic tum… DOI 10.1371/journal.pone.0298808↗
- Paper Evaluation of TAK-264, an Antibody-Drug Conjugate in Pancreatic Cancer Cell Lines and Patient-Derived Xenograft Models. DOI 10.2174/2212697x05666180516120907↗
- Alexis Diane Leal · 1 shared paper, 2024 · strength 0.18
- Christopher Hanyoung Lieu · 1 shared paper, 2024 · strength 0.18
- Robert William Lentz · 1 shared paper, 2024 · strength 0.18
- Hayley J Hawkins · 1 shared paper, 2024 · strength 0.18
- Sarah J. Hartman · 1 shared paper, 2024 · strength 0.18
- Thea Kalebic · 1 shared paper, 2018 · strength 0.07
- Anna Schreiber · 1 shared paper, 2018 · strength 0.07
- Surendra Kumar Singh · 1 shared paper, 2016 · strength 0.06
- Vasilis Vasiliou · 1 shared paper, 2016 · strength 0.06
- Manuel M. Hidalgo · 2 shared papers, 2012 · strength 0.06
- Ana De Jesus‐Acosta · 1 shared paper, 2014 · strength 0.04
- Anirban Maitra · 1 shared paper, 2014 · strength 0.04
- Daniel A. Laheru · 1 shared paper, 2014 · strength 0.04
- Robert A. Winn · 1 shared paper, 2012 · strength 0.03
- Colin D. Weekes · 1 shared paper, 2012 · strength 0.03
- Charles Erlichman · 1 shared paper, 2012 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.